 | Up a level |
Journal Article
Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E. and Harbeck, Nadia (2020). Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. npj Breast Cancer, 6 (1). LONDON: NATURE PUBLISHING GROUP. ISSN 2374-4677
Gluz, Oleg, Kolberg-Liedtke, Cornelia, Prat, Aleix 
ORCID: 0000-0003-2377-540X, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia
(2020).
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int. J. Cancer, 146 (1).
S. 262 - 272.
HOBOKEN:
WILEY.
ISSN 1097-0215
Gluz, Oleg, Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pelz, Enrico, Clemens, Michael, Warm, Matthias, Aktas, Bahriye, Kuemmel, Sherko, Pare, Laia, Krabisch, Petra, Kreipe, Hans Heinrich, Wuerstlein, Rachel, Nitz, Ulrike and Harbeck, Nadia (2018). Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial. Cancer Res., 78 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Griguolo, Gaia ORCID: 0000-0002-8782-4509, Braso-Maristany, Fara, Gonzalez-Farre, Blanca ORCID: 0000-0002-1796-7248, Pascual, Tomas ORCID: 0000-0001-8431-3183, Chic, Nuria, Sauri, Tamara, Kates, Ronald, Gluz, Oleg, Martinez, Debora, Pare, Laia ORCID: 0000-0002-4904-558X, Tsvetkova, Vassilena, Pesantez, David, Vidal, Maria, Adamo, Barbara, Munoz, Montserrat, Galvan, Patricia, Barbera, Laura, Cuatrecasas, Miriam, Christgen, Mathias, Kreipe, Hans, Monge-Escartin, Ines, Villagrasa, Patricia, Soy, Dolors, Giarratano, Tommaso, Dieci, Maria Vittoria, Conte, Pierfranco, Harbeck, Nadia, Guarneri, Valentina and Prat, Aleix
(2020).
ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
Cancers, 12 (7).
BASEL:
MDPI.
ISSN 2072-6694
Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich and Nitz, Ulrike (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755